DNA NYSE
Ginkgo Bioworks Holdings, Inc.
1W: +15.8%
1M: +75.5%
3M: +22.1%
YTD: +41.8%
1Y: -15.9%
3Y: -82.7%
5Y: -97.5%
$12.35
-0.15 (-1.20%)
Weekly Expected Move ±16.1%
$8
$10
$12
$14
$16
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (46)
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know
Beyond GLP-1 injectables, who wins the next phase for obesity drugs?
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?
Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts
Twist Bio, and Gingko rise after agreements with Lilly TuneLab
Biotech Breakout: What's in focus after Moderna's cancer win?
Ginkgo Bioworks Holdings, Inc. Q2 2026 Earnings Call Summary
Caxton Associates LLP Sells 103,802 Shares of Ginkgo Bioworks Holdings, Inc. $DNA
Palantir's Bold Biosecurity Opportunity Could Be Bigger Than Investors Think
As the GLP-1 race heats up, how can investors position themselves for the next wave of innovation?
Ginkgo Bioworks (DNA) Q1 2026 Earnings Transcript
Ginkgo Bioworks slumps 14% after projecting FY26 cash burn of $125M-$150M
Ginkgo outlines $125M-$150M 2026 cash burn guidance while expanding Nebula to 103 racks
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
Ginkgo Bioworks (NYSE:DNA) Major Shareholder Sells $91,164.15 in Stock
Insider Selling: Ginkgo Bioworks (NYSE:DNA) Major Shareholder Sells $83,942.40 in Stock
Ginkgo Bioworks (NYSE:DNA) Insider Sells $91,164.15 in Stock
Ginkgo Bioworks (NYSE:DNA) Insider Sells $83,942.40 in Stock
Insider Selling: Ginkgo Bioworks (NYSE:DNA) Insider Sells $702,508.80 in Stock
Insider Selling: Ginkgo Bioworks (NYSE:DNA) Insider Sells $672,313.95 in Stock
ProQR forms advisory board, partnership with Ginkgo as part of AI strategy
Tenaya Therapeutics Stock Jumps After New Alnylam Deal
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2025 Earnings Call Transcript
Flutter Entertainment Posts Downbeat Q4 Results, Joins Zscaler, Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session (CORRECTED)
Ginkgo Bioworks Holdings reports Q4 results
Ginkgo Bioworks Pivots To AI And Robotics After Rough Quarter
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business
Amazon's DNA: Why Hoarding Cash Is Secondary To Building Empires
Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to Know
Allegiant Travel: Cost Discipline DNA Returns, Sun Country Airlines' Upside
Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark
Why Ginkgo Bioworks Holdings, Inc. (DNA) Dipped More Than Broader Market Today
Ginkgo Bioworks Holdings, Inc. (DNA) Declines More Than Market: Some Information for Investors
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Drops Despite Market Gains: Important Facts to Note
Ginkgo Bioworks Holdings, Inc. (DNA) Increases Despite Market Slip: Here's What You Need to Know
MySize Explores Unlocking the "DNA of Fashion" Through Privacy-First Data Intelligence
Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Dips While Market Gains: Key Facts
Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts
Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment
ProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies
Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety
Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High‑Throughput Phenotyping Platform for DOE's M2PC
STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy